Rx-360 Announces the Release of the Rx-360 Supplier Assessment Questionnaire
Rx-360 has announced the release of the Rx-360 Supplier Assessment Questionnaire (SAQ). The SAQ was prepared by the Rx-360 Supplier-Led Working Group, an Rx-360 working group consisting of members from both pharmaceutical companies and leading suppliers to the pharmaceutical industry. Through this Working Group, members can share perspectives and work collaboratively to achieve greater harmonisation and efficiencies in the supply chain to better serve patients.
Pharmaceutical manufacturers and industry suppliers recognise the inefficiency and waste of resources when each individual pharmaceutical company creates its own supplier assessment questionnaire. Suppliers routinely exhaust valuable resources continuously completing slightly different forms of substantially similar questionnaires. To create the current Supplier Assessment Questionnaire, the Working Group analysed numerous sample questionnaires submitted by Rx-360 members. In addition to standardised content, document formatting and question completion was optimised for accuracy and ease of completion by suppliers.
The Rx-360 SAQ covers standard information that would be included in most supplier assessment questionnaires. The 4-part questionnaire is more detailed than most, but will decrease the number of times that questionnaires will need to be filled out by the supplier, while significantly decreasing the turn-around time back to manufacturers. The SAQ consists of four (4) modules:
• General Company Information
• Specific Site Information
• Product Supplier Appendix
• Services Supplier Appendix.
The Working Group believes the Rx-360 SAQ will create helpful efficiencies for both suppliers and pharmaceutical manufactures alike by
• Eliminating time-consuming redundancies
• Streamlining the process of approving suppliers
• Allowing comparative analysis of basic information.
The Supplier Led Working Group strongly encourages suppliers and manufacturers to consider adopting this SAQ in standard use. All modules will be available shortly for public download at the Rx-360 website.
The Supplier Led Working Group will be holding a public webinar to introduce the documents on 28 August 2014.
Anyone interested in learning more or considering use of the questionnaires is encouraged to attend. To RSVP, please register through this link: www4.gotomeeting.com/register/163722479.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance